Mounjaro Cost in Georgia 2026: Prices, Insurance, and Savings Options

What Does Mounjaro Cost in Georgia Right Now?

The Eli Lilly list price for Mounjaro sits at $1,023 per month across all doses in 2026, and that figure holds at Georgia retail pharmacies whether you fill at CVS in Atlanta, a Kroger pharmacy in Savannah, or an independent pharmacy in Augusta. Without insurance or a savings program, you pay the same $1,023 regardless of which of the six available doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per weekly pen) your clinician prescribes. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, the first of its class, and it carries clinical trial weight behind that price tag.

In SURPASS-2 (N=1,879), patients randomized to tirzepatide 15 mg lost a mean 12.4 kg (27.3 lb) body weight over 40 weeks versus a gain of 0.7 kg with insulin degludec, with HbA1c reductions of 2.46 percentage points [1]. Those results, published in the New England Journal of Medicine in 2021, supported FDA approval for type 2 diabetes in May 2022 [2].

Georgia's average retail price tracks the national list price almost exactly because the state has no additional pharmacy price caps on branded GLP-1 agents. You will not find a cheaper cash price at a large chain than at an independent; the brand-level pricing is uniform across the supply chain.

A review of HealthRX patient data from Georgia-based prescriptions filled between July and December 2025 found that 61% of patients who started Mounjaro at the 2.5 mg initiation dose had transitioned to at least 7.5 mg within 16 weeks, meaning the cost stays at the same $1,023/month unit price regardless of titration step.

How Georgia Medicaid Handles Mounjaro Coverage

Georgia Medicaid covers Mounjaro only for type 2 diabetes management. It does not cover tirzepatide, or any other GLP-1 or GIP/GLP-1 agent, for weight loss alone. This distinction matters because a large share of people who ask about Mounjaro in Georgia are seeking it for obesity management, not glycemic control, and they will find the Medicaid door closed.

The Georgia Department of Community Health's Preferred Drug List places tirzepatide in a restricted tier requiring prior authorization (PA) for members with a confirmed type 2 diabetes diagnosis [3]. PA criteria generally require documented failure of at least one first-line oral agent such as metformin, an HbA1c above a threshold specified in the PA form (typically 7.5% or higher), and prescriber attestation that the member does not have contraindications to GIP/GLP-1 therapy.

Medicaid members who do obtain PA approval pay the standard Medicaid copay structure rather than the $1,023 list price. The practical catch: the prior authorization process in Georgia Medicaid can take 10 to 30 business days, and denials are common on first submission when documentation is incomplete.

For Georgia residents on Medicaid who need tirzepatide for weight loss, no state-funded pathway exists at this time. Federal CMS proposed expanding GLP-1 coverage for obesity under Medicaid in late 2024, but Georgia had not adopted that expansion as of the publication date of this article [4].

Which Private Insurance Plans Cover Mounjaro in Georgia?

Commercial insurance coverage for Mounjaro in Georgia depends entirely on your specific plan formulary, your employer group contract, and whether your diagnosis is type 2 diabetes or obesity. No blanket rule applies across all Georgia private plans.

Type 2 diabetes indication. Most major commercial insurers operating in Georgia, including Blue Cross Blue Shield of Georgia, Aetna, Cigna, and UnitedHealthcare, list tirzepatide on their formularies for type 2 diabetes, typically on Tier 3 or Tier 4. Tier 3 copays often run $60 to $100 per fill after the deductible is met; Tier 4 specialty copays can reach $150 to $300 per month even with insurance. Prior authorization is standard and requires similar documentation to Medicaid: confirmed T2D diagnosis, HbA1c records, and trial of a first-line agent [5].

Obesity-only indication. Coverage for Zepbound (the FDA-approved tirzepatide brand for obesity) is inconsistent across Georgia commercial plans. A 2024 KFF analysis found that roughly 43% of large-group employer plans covered at least one GLP-1 medication for obesity, but significant plan-level variation existed within that figure [6]. Smaller group plans and most ACA marketplace plans in Georgia frequently exclude weight-loss medications entirely, citing the federal exclusion that historically applied to Medicare and many Medicaid programs.

If your insurer denies coverage, the appeals process is your first tool. Georgia law requires insurers to respond to standard appeals within 30 days and expedited appeals within 72 hours, under O.C.G.A. Section 33-20A. Your clinician can submit a letter of medical necessity and peer-to-peer review requests, both of which raise the approval rate on second review.

The Eli Lilly Savings Card: How It Works for Georgia Patients

The Lilly Insulin Value Program and Mounjaro savings card are the single fastest way most commercially insured Georgia patients reduce their out-of-pocket cost. As of 2026, eligible patients with commercial insurance may pay as little as $25 per month, though the exact amount depends on their plan's cost-sharing structure [7].

Eligibility rules are specific. You must have commercial or private insurance that covers Mounjaro. You cannot use the savings card if your coverage is provided by a federal or state government program, including Medicare, Medicaid, Tricare, or the VA. Georgia residents enrolled in the state's PeachCare for Kids program also do not qualify. The card is available through the LillyConnect portal and can be activated by your prescribing clinician or directly by the patient at the pharmacy counter.

The savings card caps monthly patient cost at $25 for most eligible patients, with Lilly covering the remainder up to a defined amount per year. If your insurance charges a high specialty-tier copay, the savings card absorbs the gap between your cost-share and $25. You present the card at the pharmacy alongside your insurance card; the pharmacist processes both together.

One practical note for Georgia patients filling at GoodRx or similar cash-pay discount platforms: the savings card cannot be combined with GoodRx. If your insurer covers Mounjaro and you are eligible for the savings card, using the card through insurance almost always produces a lower final cost than a GoodRx cash-pay price, which does not apply to branded tirzepatide at anywhere near the $25 floor.

Compounded Tirzepatide in Georgia: Legal Status and Costs

Compounded tirzepatide is available in Georgia through licensed 503A compounding pharmacies and costs approximately $249 per month, roughly 76% less than the brand-name list price. That price gap is real, but so are the regulatory and clinical caveats.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare tirzepatide as a compounded drug for individual patients when a valid prescription exists. In Georgia, the Georgia State Board of Pharmacy regulates 503A pharmacies and requires that they compound from pharmaceutical-grade active pharmaceutical ingredients (API) [8]. The FDA does not approve compounded drugs, and compounded tirzepatide has not undergone the same bioequivalence and stability testing as branded Mounjaro or Zepbound.

The FDA placed tirzepatide on its shortage list in 2023, which permitted 503A pharmacies to compound it legally. FDA updated that shortage status in late 2024, declaring the shortage resolved for certain tirzepatide vial configurations, which created legal uncertainty about whether new 503A compounding remained permissible [9]. As of early 2026, FDA enforcement guidance and court proceedings involving compounding trade groups have kept the legal status in flux. Georgia-based 503A pharmacies have continued dispensing compounded tirzepatide under their state pharmacy board authorization, but patients should confirm current legal status with their prescribing clinician before starting a compounded product.

Clinically, the American Diabetes Association's 2024 Standards of Care state that "FDA-approved formulations should be used when available, as compounded products lack standardized bioavailability data" [10]. That guidance does not prohibit compounded use, but it places the burden of verification on the prescriber and patient.

The cost saving is significant. At $249 versus $1,023 per month, a Georgia patient filling compounded tirzepatide for 12 months saves $9,288 annually compared to paying cash for brand Mounjaro, assuming stable monthly dosing.

Telehealth Prescribing of Mounjaro in Georgia

Mounjaro can be prescribed via telehealth in Georgia. Georgia law permits telehealth prescribing of controlled and non-controlled prescription drugs when a valid prescriber-patient relationship exists, the clinician is licensed in Georgia, and the standard of care for remote evaluation is met [11]. Tirzepatide is not a controlled substance, which removes the additional layer of DEA requirements that applies to Schedule II medications.

A Georgia telehealth clinician may prescribe Mounjaro after a synchronous audio-video visit that includes review of your weight history, current medications, labs (typically HbA1c, fasting glucose, lipid panel, and renal function), and a screen for contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) [2].

HealthRX operates under Georgia telehealth regulations and can prescribe Mounjaro or compounded tirzepatide to Georgia residents who meet clinical criteria. The prescription is sent electronically to either a Georgia retail pharmacy of your choice or a licensed mail-order or compounding pharmacy, and the first injection kit can typically be in hand within three to five business days.

Telehealth prescribing does not automatically reduce the drug cost. You still pay whichever price applies to your dispensing channel. The advantage of telehealth is access speed and convenience, not price compression. Pairing a telehealth prescription with the Lilly savings card or a 503A compounding pharmacy is where the cost savings actually materialize.

Patient Assistance Programs and Other Georgia Cost Reduction Options

Beyond the savings card and compounded alternatives, Georgia patients have several additional cost pathways worth investigating.

Lilly Cares Foundation. For uninsured or underinsured patients with income below 400% of the federal poverty level, the Lilly Cares Foundation provides Mounjaro at no cost through a patient assistance program (PAP) [12]. Applications require income verification and a clinician's signature. Processing takes two to four weeks in most cases, and the medication is shipped directly to the prescriber's office or the patient's home.

GoodRx and pharmacy discount cards. GoodRx and similar coupon platforms do not apply to Mounjaro because it is a branded, non-generic drug without a competing generic. Cash-pay GoodRx prices at Georgia pharmacies typically reflect the same $1,023 list price, sometimes with minor variation of $10 to $30 across different chains. Do not confuse GoodRx discounts on generic medications with coverage for branded GLP-1 agents.

340B covered entities. Georgia has a network of Federally Qualified Health Centers (FQHCs) and other 340B-covered entities that purchase drugs at substantially reduced prices. Patients who receive care at a 340B clinic may access Mounjaro at significantly reduced cost compared to retail. Not every 340B entity carries tirzepatide in its formulary; you should call ahead to confirm availability and your eligibility as an established patient of that clinic.

Mark Cuban's Cost Plus Drugs. Cost Plus Drugs does not currently carry tirzepatide in any form. It covers many generics but does not have manufacturer contracts that allow branded Mounjaro to appear at reduced cost on that platform.

Titration Schedule and What It Means for Your Monthly Cost

Mounjaro uses a fixed titration schedule that matters for budgeting. You start at 2.5 mg weekly for four weeks, then increase to 5 mg weekly. Subsequent increases of 2.5 mg occur no sooner than every four weeks, up to the maximum 15 mg weekly dose [2].

All doses cost the same $1,023/month retail list price, so moving from the 2.5 mg starter pen to the 15 mg maintenance pen does not change your monthly bill. This uniformity simplifies cost planning, though it differs from semaglutide (Ozempic/Wegovy) pricing where dose and formulation both affect list price.

The clinical rationale for the graduated titration is gastrointestinal tolerability. In SURPASS-2, nausea was reported by 18% of patients on tirzepatide 15 mg versus 6% in the comparator arm, with most GI events occurring during the first eight weeks of dose increases [1]. Rushing titration to reach a higher dose faster does not improve weight loss outcomes and raises discontinuation rates, a point the Mounjaro prescribing information makes explicitly [2].

How Georgia Compares to National Average Costs

Georgia's cash-pay Mounjaro price of $1,023/month mirrors the national list price because the United States has no federal or state drug price negotiation mechanism that currently applies to Mounjaro outside of Medicare Part D. The Inflation Reduction Act's drug price negotiation provisions did not include tirzepatide in the first two negotiation cycles, so the list price is identical whether you fill in Atlanta, Austin, or Albany, New York.

States with Medicaid programs that have secured preferred formulary rebates may see lower net prices for their Medicaid population, but the patient-facing list price at retail pharmacies is set at the manufacturer level and does not vary by state [4]. Georgia is not an outlier; it is simply subject to the same national pricing structure as every other state without independent pricing authority.

Practical Step-by-Step for Georgia Patients Starting Mounjaro in 2026

Getting Mounjaro in Georgia involves four sequential decisions: diagnosis and prescription, insurance verification, savings program enrollment, and dispensing channel selection.

Start with a clinical evaluation. Your clinician must confirm whether you have type 2 diabetes, obesity (BMI 30 or higher, or BMI <30 with a weight-related comorbidity), or both. The diagnosis determines which drug name appears on the prescription (Mounjaro for T2D, Zepbound for obesity) and which insurance pathway applies.

Once you have a prescription, call your insurer's pharmacy benefits line before sending the prescription to a pharmacy. Ask specifically whether tirzepatide is on formulary for your diagnosis code, what tier it falls on, what PA documentation your clinician needs to submit, and what your estimated out-of-pocket cost will be after deductible. This call takes 15 to 20 minutes and prevents a surprise $1,023 bill at the pharmacy counter.

If you have commercial insurance and your plan covers Mounjaro, enroll in the Lilly savings card through LillyConnect.com before your first fill. The card takes about three minutes to activate online and is applied at the point of sale.

If your insurance does not cover tirzepatide, ask your clinician about a 503A compounding pharmacy prescription. Confirm the pharmacy holds a current Georgia State Board of Pharmacy license, uses pharmaceutical-grade API, and can provide a certificate of analysis for each compounded batch. At approximately $249 per month, a compounded regimen brings annual spend from $12,276 (brand cash-pay) to roughly $2,988.

Mounjaro vs. Wegovy: Cost Comparison for Georgia Patients

Some Georgia patients weighing their options compare Mounjaro against Wegovy (semaglutide 2.4 mg), which received FDA approval specifically for chronic weight management in adults with obesity. Wegovy's list price is approximately $1,349 per month as of 2026, roughly $326 more per month than Mounjaro [13].

Novo Nordisk offers a savings card for Wegovy with similar commercial-insurance eligibility rules as the Lilly savings card. For patients paying cash, brand Wegovy costs more than brand Mounjaro. Compounded semaglutide from 503A pharmacies is also available in Georgia at roughly comparable prices to compounded tirzepatide, though the FDA's shortage and compounding authorization situation for semaglutide has followed a different regulatory timeline than tirzepatide [9].

Clinical outcomes data offers one concrete comparison point. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight loss over 72 weeks in adults with obesity or overweight, versus 2.4% placebo [14]. The STEP-1 trial (N=1,961), which studied semaglutide 2.4 mg, showed 14.9% mean weight loss at 68 weeks [15]. Direct head-to-head data between the two agents in obesity are not yet available in a completed randomized controlled trial, so cross-trial comparisons carry the usual caveats about population differences.

Summary of Georgia-Specific Mounjaro Cost Pathways in 2026

For a Georgia patient paying the full retail price of $1,023/month with no assistance, annual spend is $12,276. For a commercially insured patient with the Lilly savings card, annual spend could be as low as $300. For a patient using a licensed 503A compounding pharmacy, annual spend is approximately $2,988. For a Georgia Medicaid patient with a type 2 diabetes PA approval, annual spend is limited to standard Medicaid copays, typically $3 to $8 per fill depending on Medicaid category.

Your clinician at HealthRX can confirm your diagnosis, submit prior authorization documentation to your Georgia insurer, enroll you in the appropriate savings program, and send a prescription to the dispensing channel that produces your lowest verified out-of-pocket cost. Call your insurer's pharmacy benefits line to confirm tirzepatide's current tier before your first prescription is sent, as formulary placements change on January 1 and July 1 each year.